Global Market for Operating Room Equipment to be Worth USD 4.05 Billion by 2019

Operating Room EquipmentAn operating theatre or operating room is a specially-fitted room in a hospital for performing surgical operations. An operating room comprises a myriad of specially-designed equipment such as operating tables, surgical booms, operating room lights, imaging displays as well as integration systems for operating rooms. According to a report by Transparency Market Research, a U.S.-based market research firm, the operating room equipment market is expected to reach USD 4.5 billion by 2019.

Browse the full report with TOC:

According to this report, the largest segment within the operating room equipment market in 2012 was the operating tables segment. In 2012, the total revenue share of the segment was valued at 30.6% of the total market, amounting to USD 815.5 million.

The other segments within this market that are poised to show promising growth are: surgical booms followed by operating room integration systems, largely due to the growing emergence of hybrid operating rooms. Aspects such as equipment integration and space management are integral to the concept of a hybrid operating room.

Here are some key factors attributed to the growth of the operating room equipment market over the forecast period of 2013 to 2019:

  • A growing number of Ambulatory surgical centers globally
  • A rising demand for hybrid operating rooms that are based on cutting-edge technology (especially in the developed American and European markets)
  • Technological advances and product innovation
  • A spike in the aged population worldwide that is expected to provide an indirect boost to operation theatre equipment (as this age group is susceptible to health disorders as compared to the younger population)

While there are several factors likely to give the market a push, this market is certainly not devoid of restraints. These include factors such as high equipment cost that is likely to act as a deterrent to healthcare institutions in replacing old equipment with advanced one. This restraint is especially pronounced for those healthcare providers that operate on a restricted budget.

The regional market share for Operating Room Equipment

According to the report published by Transparency Market Research, North America and Europe constituted the largest markets (by region) for operating room equipment. In these regions, healthcare centers and hospitals already comprise all the essential equipment required in an operating room, hence the growth of this market will largely be propelled by replacement/upgrading to introduce modern technologies and machines in the operating room.

On the other hand, various emerging countries in the Asia Pacific region will show a greater inclination towards the purchase of new operating room equipment as healthcare awareness rises here, along with disposable income. Another factor of significance in the Asia-Pacific region is the growth of medical tourism. Patients from all over the globe are flying into countries such as South Korea, Thailand, India and Malaysia to undergo various surgical procedures and treatments primarily attracted by the low cost of treatments here. Thus, it is evident that a number of healthcare providers are investing in new operating room equipment in order to make the most of this medical tourism boom and to offer the best services to their clientele.

Browse full PDF with TOC: Operating Room Equipment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

The leading players in the operating room equipment market account for nearly 60% of the total revenue generated in 2012. These key players include names such as Stryker Corporation, Getting Group, TRUMPF GmbH + Co, and Steris Corporation.

Thus, as the number of surgical procedures rises worldwide, the operating room equipment market can expect steady growth. However, this market will continue to face a concern in the form of the high costs associated with operating room equipment, and healthcare providers that run on a tight budget may instead look at alternatives such as purchasing used or refurbished operating room equipment.

Biopreservation Market – An Overview of Growth Factors

Bio-prservation market

Modern day medicine is long out of the genomic era where decoding human genome was considered the only way to find the genetic basis and the eventual cure for human diseases. It is in a phase where new disciplines are being discovered by fusing manipulative engineering with medical sciences to provide remedies for various autoimmune diseases, degenerative diseases and even aging.

Browse full Report with TOC:

With advances in the field of medicine and cell-based disciplines such as tissue engineering, cell transplantation, biopharmaceutical research and cell therapy, the demand for proper procurement, preservation, processing and banking of the biospecimen acquired, either from natural sources or through laboratory experiments is also rising.

Biopreservation is a technique that controls the biochemical reactions of certain organisms present in cells, tissues or any natural body so as to sustain functionality even after the natural body is exposed for a prolonged time to otherwise lethal conditions. Biopreservation is undertaken by the virtue of controlled temperatures and used of substances such as liquid nitrogen among others.

Formulating and implementing effective ways for biopreservation is as necessary as the acquisition of biospecimen. This is essentially necessary to process, store, transport, distribute and ensure an on-demand supply, extended shelf life and stabilization of these products.

The recent times have seen a huge rise in research activities in various fields of biotechnology leading to an added demand for effective biopreservation instruments and products. This includes a rise in demand for equipment such as refrigerators, freezers, liquid nitrogen tanks and consumables, along with media and laboratory information management systems (LIMS).

The global biopreservation market, which was valued at about 1.95 billion in 2012, is estimated to reach a value of USD 5.69 billion in 2019 with a growth rate of 16.7% through the years 2013 to 2019 according to new market studies.

It is estimated that the segment of consumables will show the highest growth rates in this market. The growth would be driven by the rise in demand for cryo vials, cryo bags, gloves, cryo tubes and other consumables from existing biopreservation organizations.

Need for automation in storage facilities will lead to the growth of market for laboratory information management systems. This demand is estimated to be seen majorly in developed economies such as US, Japan, Canada, Germany and France, however, steady growth in demand is also anticipated from developing economies.

Browse full PDF with TOC: Biopreservation Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

The major applications of the field are biobanking, drug discovery and regenerative medicine. According to data gathered in the year 2012, the biobanking segment of applications ruled the market by capturing its major share. It is estimated that the same segment will keep its lead in the coming years as well. This is assumed based on the recent approval of new biobanking projects in developing economies such as  India, Korea, China, Singapore, Malaysia, Brazil and many African countries.

Baby Boomers Likely to Push Global Anti-Aging Market to $191.7 billion by 2019

anti-aging-marketAnti-aging is proving to be a lucrative business with products and services such as anti-wrinkle treatments and products, hair restoration treatments, hair color, radio frequency-device based treatments, and breast augmentation becoming much sought after worldwide. In a new market report published by U.S.-based market intelligence firm Transparency Market Research, the global market for these anti-aging treatments and products will grow to USD 191.7 billion by 2019, from being worth USD 122.3 billion in 2013. This marks a compounded annual growth rate (CAGR) of 7.8% between 2013 and 2019.

Browse full Report:

What Are The Major Segments Within The Anti-Aging Market?

From the biological perspective, aging is defined as the deterioration and/or decline of functional properties at three main levels: cells, tissues and organs. This process is essentially a cycle of biochemical activities that are brought about in the body by various factors that work both internally and externally. Arguably, age affects the beauty, fitness, and health of an individual.

The anti-aging market comprises a number of technologies and products as well as services and devices aimed at mitigating or reversing the signs of aging. A number of technological breakthroughs and advances have shaped the attributes of the anti-aging industry as well as the way market players’ reach in the market.

As compared to anti-aging devices and services, the category of anti-aging products demonstrates easy adoptability.

The anti-aging services segment is classified as cosmetic surgeries/procedures and non-invasive treatments, both of which are required to be practiced by certified practitioners, plastic surgeons, or trained and qualified beauty therapists. The market for anti-aging services is projected to demonstrate a CAGR of 5% between 2013 and 2019.

The market for anti-aging products is the largest in terms of revenue generation. The products market also holds potential for the introduction of new, safe, and efficient products.

Browse full PDF with TOC: Anti-aging Market -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

This is a market that is still considered to be in its evolutionary stage, and it faces a certain degree of skepticism among consumers. However, the compliance of manufacturers with stringent regulatory mandates and the use of cutting-edge technology have restored faith in these products, services and devices to some extent.

What are the factors fueling the anti-aging market?

The anti-aging market is of special importance from the standpoint of the generation of Baby Boomers – a generation that was born between 1946 and 1964. This is a generation that witnessed a transformational era of revolutions and inventions. The Baby Boomers—widely regarded as the most successful generation in the 20th century— is now an aging generation that is nearing the age of retirement.

This makes them a consumer segment that shows maximum potential for the consumption of anti-aging products, services, and devices. The awareness among this generation pertaining to the availability of anti-aging products in the market is growing.

According to reports, the first Baby Boomers reached the age of retirement in 2012. Figures also indicate that over the next 18 years, nearly 8000 individuals per day from this generation will turn 65.

The geographical perspective

Asia-Pacific and Rest of the World (RoW) are two regions that are projected as being most lucrative for the anti-aging market. Within this region, countries such as Japan, China, South Korea and India are expected to emerge as the most sought-after destinations for anti-aging treatments and cosmetic surgeries.

This aspect is only bolstered by the fact that the governments of these nations are introducing various methods to promote medical tourism. In the RoW segment, Mexico and Brazil are being viewed as companies that will attract a significant share in the anti-aging market. These countries are witnessing rapid development on the economic front and there is a simultaneous growth in awareness pertaining to anti-aging treatments, therapies and products among both men and women. This has paved the way for Brazil and Mexico to rank among the most attractive markets in the future.

Pulmonary Drug Delivery Systems Market Expected to Reach USD 28.7 Billion Globally in 2019: Transparency Market Research

Medical_Devices copyAccording to a new market report published by Transparency Market Research “Pulmonary Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019” the global pulmonary drug delivery systems market was valued at USD 21.03billion in 2012 and is expected to grow at a CAGR of4.5% from 2013 to 2019, to reach an estimated value of USD 28.70billion in 2019.

Browse Global Pulmonary Drug Delivery Systems Market Report with Full TOC:

Pulmonary drug delivery systems use the respiratory tract to deliver medications to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The history of use of these systems dates back to over 60 years ago, when these systems were initially indicated for treating only respiratory diseases – asthma and COPD. Continued development in this area facilitated their application in the treatment of other diseases as well, including cystic fibrosis and diabetes. Exubera was the first inhalable insulin launched by Pfizer Ltd. and Nektar Pharma for treating diabetes, in 2006. However,owing to its poor sales performance, Exubera was withdrawn from the market within a yearof its launch which led other partnerships such as Alkermes/Eli Lilly and Aradigm/Novo Nordisk to abandon the development process of inhalable insulin therapies. Currently,Afrezza by MannKind Corporation is the only inhalable insulin under review by the U.S. FDA and is likely to be approved for marketing in the U.S. by mid-2014.

The global market for pulmonary drug delivery systems includes metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. Initially, MDIs used chlorofluorocarbons (CFCs) as propellants.Later due to rising environmental concerns and pressure from Montreal Protocol (1987) recommendation to phase out CFCs, manufacturers started using hydrofluoroalkanes (HFAs) that are considered as safe propellants causing negligible threat ofozone depletion.MDIs accounted for the largest share (56.8%) of the total global pulmonary drug delivery systems market in 2012 and this segment is expected to grow at a CAGR relatively lower than that for DPIs and nebulizer market segments. This is primarily because of the environmental concerns related with the use of CFCs, which led to ban on CFC-based inhalers. Although manufacturers have now started using HFAs the fact that HFAs also emit gases causing ozone layer depletion has led manufacturers to shift their focus more towards the development of DPIs. During the forecast period 2013 to 2019, DPIs are expected to witness greater demand than MDIs owing to propellant free nature of these systems. The market for nebulizers has been anticipated as the fastest growing segment of the pulmonary drug delivery systems market mainly due to the technical advances leading to portability of these devices and rising demand for home based care. The global pulmonary drug delivery systems market has also been segmented on the basis of their application in treating various diseases such as asthma, COPD and cystic fibrosis.

Among the four major geographies of the world, North America and Europe accounted for the first and second largest market shares in 2012 of the global pulmonary drug delivery systems market.The market in these regions is characterized by a range of factors such as patent expiry of many blockbuster inhaler brands, increasing prevalence of asthma and COPD, focus on reducing treatment costs, growing environmental concerns and aging population.Asia-Pacific held the third largest share of the global pulmonary drug delivery systems market in 2012. The region being home to more than half of the world’s population represents a large pool of patients suffering from respiratory diseases such as asthma and COPD, and thus, represents a high growth potential market for pulmonary drug delivery systems, estimated to grow at a CAGR of 6.6% during the forecast period.Emerging economies of India and China are expected to favor the positive growth of pulmonary drug delivery systems market in the region by contributing to the rise in healthcare expenditure.

The global market for pulmonary drug delivery systems is dominated by companies such as GlaxoSmithKline, plc, Boehringer Ingelheim, AstraZeneca, Merck & Co., Philips Respironics and Omron Healthcare. These players collectively accounted for more than 75% of the global pulmonary drug delivery systems market revenue in 2012.Some other players operating in this market include Novartis AG, CareFusion Corporation, 3M Health Care, PARI Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Allied Healthcare Products, Inc., and GF Health Products Inc.

Browse full PDF with TOC: Pulmonary Drug Delivery Systems Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

The global pulmonary drug delivery systems market is segmented as follows:

Pulmonary Drug Delivery Systems Market, by Product Type

  • Metered Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Nebulizers

Pulmonary Drug Delivery Systems Market, by Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis

Pulmonary Drug Delivery Systems Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Defibrillators Market is Expected to Reach USD 14.2 Billion Globally in 2019 Transparency Market Research

tmrlogoAccording to a new market report published by Transparency Market Research “Defibrillators Market (Advanced Life Support, Automated External Defibrillators, Implantable Cardioverter Defibrillators, Wearable Defibrillators)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019” the global defibrillators market was valued at USD 9.3 billion in 2012 and is expected to grow at a CAGR of 6.2% from 2013 to 2019, to reach an estimated value of USD 14.2billion in 2019.

Browse Global Defibrillators Market Report with Full TOC:

Defibrillator devices are used to treat life-threatening cardiac arrhythmias, particularly ventricular fibrillation and pulseless ventricular tachycardia. These devices provide an electrical shock, having energy 40 – 400 Joule, to the heart muscles which terminates the arrhythmia and restores the normal sinus rhythm in the heart. Since the defibrillator devices are very useful in preventing deaths due to sudden cardiac arrest (SCA), the large number of SCA incidences across the globe is the major driver for the growth of this market.


Growing incidences of cardiovascular diseases and disorders combined with aging of baby boomer population in the U.S. are contributing to the growth of the global defibrillators market.Furthermore, the market is more driven by demand from emerging countries from Asia-Pacific and the Middle-East. Increasing trend towards installations of AEDs at workplaces by businesses is expected to serve as a good opportunity for the growth of global defibrillators market.

The global defibrillators market has been segmented on the basis of product types, end-users and geographic regions. On the basis of defibrillator types, the market is divided into advanced life support (ALS) defibrillators, automated external defibrillators (AEDs), implantable cardioverter defibrillators (ICDs) and wearable defibrillators. In 2012, implantable defibrillator devices accounted for the largest share by revenue of the global defibrillators followed by ALS defibrillators.The global rise in the healthcare infrastructure which include state-of-the-art hospitals and ambulances equipped with advanced medical devices is seen as a driver for ALS defibrillator segment.

Browse full PDF with TOC: Defibrillators Market is Expected to Reach USD 14.2 Billion Globally in 2019 Transparency Market Research

The report also provides market estimations for the end-users of defibrillator devices during the forecast period of 2013 to 2019. The market has been categorized on the basis of end-users into five major segments, namely, hospitals, home, public access, emergency medical services and business workplace. In 2012, the hospitals as an end-user category shared more than 90%of the global defibrillator market.Other segments which are expected to grow rapidly during the forecast period are public access and business workplace. The government initiatives for creating awareness about the usefulness of AEDs in SCA will be the crucial factor for the growth of this market. Although the FDA initiatives to tighten the AED approval process, through pre-market approval (PMA), are likely to impact the market negatively, the grace period implementing changes is considerable enough for manufacturers in the defibrillators market.

Geographically, North America is the largest market for defibrillator devices and is expected to retain its top position throughout the forecast period. The rising awareness about the SCA and defibrillators in the USA and Canada is contributing to overall growth of defibrillators market in the region. In addition, legislations requiring installation of AEDs for public access and ‘Samaritan Laws’ providing immunity to first responders are driving factors for the market.Europe was the second largest market for defibrillator devices in 2012. During the forecast period, 2013 to 2019, Asia-Pacific and Middle-East are expected to grow at a faster pace than North America and Europe owing to the large patient base, increasing incidences of cardiovascular diseases and rising per capita expenditure on healthcare. The strengthening of economies in the Asia-Pacific and the subsequent rise in the healthcare infrastructure are propelling the market for defibrillators in this region.

The global defibrillators market is dominated by few major players such as Boston Medical Corporation, Medtronic, Inc. Philips Healthcare, St. Jude Medical, Inc. and Zoll Medical Corporation (a subsidiary of Asahi Kasei Corporation).

The global defibrillators market is segmented as follows:

Global Defibrillators Market, by Product Category

  • Advanced Life Support (ALS) Defibrillators
  • Automated External Defibrillators (AEDs)
  • Implantable Cardioverter Defibrillators (ICDs)
  • Wearable Defibrillators

Global Defibrillators Market, by End-Users

  • Hospitals
  • Home
  • Public Access
  • Emergency Medical Services
  • Business Workplace

Global Defibrillators Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Middle-East
  • Latin America
  • Africa

Drug Device Combination Products Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

Drug Device Combination Products MarketThis report studies the global market for drug device combination products from the perspective of product types. The market is thus segmented into drug eluting stents, infusion pumps, bone graft implants, photodynamic therapy, wound care combination devices, inhalers, transdermal patches and others including intraocular implants and drug eluting beads. The market for all these product segments is also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD billion.

Browse the full report with complete TOC:

Each of the segments have been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD billion, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size.

A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for drug eluting stents and infusion pumps. A chapter on recommendations for existing and new entrants is also provided in this report.

Some of the major players profiled in this report are Boston Scientific Corporation, Abbott Laboratories, Allergan, Inc., Bayer Healthcare, Medtronic Inc., Bausch and Lomb, Inc. All these market players are profiled in this report via parameters such as company overview, financial overview, business strategies, product portfolio and recent developments.

Browse full PDF with TOC: Drug Device Combination Products Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019

High incidence rates of chronic pain causing diseases, prostate cancer, diabetic retinopathy, cardiovascular diseases, colorectal cancer, asthma, obesity along with rapidly aging global population also form the key drivers for the global drug device combination products market. Government and NGO initiatives to promote drug delivery implants, rising number of interventional cardiologists and increase in the demand for minimally invasive surgeries are some of the other factors propelling the growth of the market. Introduction of biodegradable drug delivery technologies will serve as future growth opportunities for various drug device combination products. However, product recalls act as a major growth restraint for the market due to incidences such as adverse side effects to the patient. Also, these products form a challenge to FDA owing to their classification overlapping the regulated products and thus complicating their approval process.

Geographically, North America dominated the global drug device combination products market and is expected to continue to lead in terms of revenue generation throughout the forecast period. The market in North American region was valued at USD 28.5 billion in the year 2012.Asia-Pacific is considered as the most lucrative market for drug device combination products owing to the increase in incidences of cardiovascular diseases, diabetes related disorders and obesity through 2019. The leading players in the market for drug device combination products are Abbott Laboratories, Inc., Medtronic, Inc., Boston Scientific Corporation, CareFusion Corporation, Allergen, Inc. and others.
Browse more market research reports: Transparency Market Research

Nanomedicine Market is Expected to Reach USD 177.60 Billion Globally in 2019: Transparency Market Research

Nanomedicine MarketTransparency Market Research is Published new Market Report Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) – Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 – 2019,” .The market for nanomedicine was valued at USD 78.54 billion in 2012 and is expected to reach a value of USD 177.60 billion in 2019, growing at a CAGR of 12.3% from 2013 to 2019.

Browse the full report with complete TOC:

The advent of new applications and technology in the field of nanomedicine will be one of the major growth factors for the global nanomedicine market. In addition, increase of funding aimed at boosting the research activities pertaining to nanomedicine by the government as well as private institutions will expedite the process of commercialization of new products and hence will drive the market. Other driving factors include rising base of geriatric population, presence of high unmet medical needs and rising worldwide incidences of chronic diseases.

The global nanomedicine market by applications was dominated by the oncology market with a market share of approximately 38.0% in 2012 on account of the presence of high number of commercialized products in this segment. Development of nanomedicine products enabling drugs crossing blood brain barrier and targeting the tumor in brain and at other sites in the body will prove to be a significant future growth driver for this market.


However, the global cardiovascular market for nanomedicine is the fastest growing application segment. Factors such as the presence of large patient prevalence coupled with rising demand for nanotechnology enabled drugs and devices catering to this segment, attribute to its high growth rate.

Browse full report with TOC: Nanomedicine Market – Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 – 2019

North America dominated the market in 2012 and is expected to maintain its market position till 2019. However, theAsia-Pacific market is estimated to grow at a faster pace (CAGR of 14.6% from 2013 to 2019).Europe is expected to grow at a relatively higher rate compared to North America owing to constantly improving regulatory framework and the presence of an extensive product pipeline portfolio.

Some of the key players in the global nanomedicine market include GE Healthcare, Merck & Co Inc., Abbott Laboratories, Pfizer Inc., Nanosphere Inc., Mallinckrodt plc, Teva Pharmaceutical Industries Ltd., Sigma-Tau Pharmaceuticals Inc., Celgene Corporation, Novavax, Inc.; Life Technologies, MagArray, Inc., Gilead Sciences Inc. and others.

The global nanomedicine market is categorized into the following segments:

Nanomedicine Market by Application

  • Neurology
  • Cardiovascular
  • Anti-Inflammatory
  • Anti-Infectives
  • Oncology
  • Others

Nanomedicine Market by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Browse more market research reports: Transparency Market Research